Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation

Fig. 6

FAM167A contributes to BCR-ABL-independent TKI resistance in vivo. A Schedule for experiments and schematic showing the mouse model. B Volume of established K562R tumors in mice treated with vehicle or 10 mg/kg/day imatinib with or without the anti-FAM167A neutralizing antibody or isotype control (2 mg/kg/3 days). C Body weight of the mice. D Photograph of tumors collected from the mice in each group on Day 10 of treatment. E Tumor weight on Day 10 of treatment. F Hematoxylin and eosin (HE) staining, immunohistochemical staining of tumor sections with anti-Ki-67 and anti-NIK antibodies, and TUNEL staining. Scale bars, 100 μm. Data are representative of three (B-F) independent experiments (error bars, s.d. of five (B, C, E, F) mice or samples). Unpaired two-tailed t-test; *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant

Back to article page